pdf   xlsx method abbreviations

ovarian cancer (OC), Immune checkpoint association versus nivolumab based treatment, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.44, 1.42]< 10%1 study (1/-)78.5 %NAnot evaluable crucial-
progression or deaths (PFS) 0.53 [0.34, 0.82]< 10%1 study (1/-)99.8 %NAnot evaluable important-
objective responses (ORR) 3.28 [0.41, 26.42]> 10%1 study (1/-)86.6 %NAnot evaluable non important-

safety endpoints 00

AE (grade 3-4) 1.64 [0.74, 3.64]< 10%1 study (1/-)11.1 %NAnot evaluable non important-
AE leading to death (grade 5) 2.18 [0.38, 12.47]< 10%1 study (1/-)19.2 %NAnot evaluable non important-
TRAE (grade 3-4) 2.28 [1.01, 5.15]< 10%1 study (1/-)2.4 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.04 [0.02, 53.53]< 10%1 study (1/-)49.2 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Acute kidney injury TRAE (grade 3-4) 2.10 [0.07, 64.18]< 10%1 study (1/-)33.7 %NAnot evaluable non important-
Adrenal insufficiency TRAE (grade 3-4) 2.10 [0.07, 64.18]< 10%1 study (1/-)33.7 %NAnot evaluable non important-
Anaemia TRAE (grade 3-4) 4.44 [0.48, 41.25]< 10%1 study (1/-)9.6 %NAnot evaluable non important-
Arthritis TRAE (grade 3-4) 2.10 [0.07, 64.18]< 10%1 study (1/-)33.7 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 1.60 [0.26, 10.00]< 10%1 study (1/-)30.9 %NAnot evaluable non important-
Dyspnoea TRAE (grade 3-4) 2.10 [0.07, 64.18]< 10%1 study (1/-)33.7 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 0.24 [0.03, 2.27]< 10%1 study (1/-)89.1 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 1.04 [0.02, 53.53]< 10%1 study (1/-)49.2 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 1.04 [0.02, 53.53]< 10%1 study (1/-)49.2 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.52 [0.02, 15.72]< 10%1 study (1/-)64.6 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 2.13 [0.19, 24.25]< 10%1 study (1/-)27.3 %NAnot evaluable non important-
Pancreatitis TRAE (grade 3-4) 2.10 [0.07, 64.18]< 10%1 study (1/-)33.7 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 1.04 [0.02, 53.53]< 10%1 study (1/-)49.2 %NAnot evaluable non important-
Pyrexia TRAE (grade 3-4) 1.04 [0.02, 53.53]< 10%1 study (1/-)49.2 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 1.04 [0.14, 7.71]< 10%1 study (1/-)48.4 %NAnot evaluable non important-
Thrombocytopenia TRAE (grade 3-4) 6.59 [0.32, 135.04]< 10%1 study (1/-)11.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons